| |
N = 124 patients
|
|
Age (Y)
|
32 ± 2.8
|
|
Gender (M/F)
|
5 / 119
|
|
AN-R type
|
90 (73%)
|
|
AN-BP type
|
34 (27%)
|
|
Duration of AN since diagnostic (Y)
|
7.9 ± 5.7
|
|
BMI
|
12.3 ± 2,5
|
|
HR (bpm)
|
61.6 ± 17.2
|
|
SBP (mm Hg)
|
99.2 ± 12
|
|
DBP (mmHg)
|
65.6 ± 10.6
|
|
Body composition (DEXA)
|
|
FFM (Kg)
|
28.8 ± 4.8
|
|
FM (%)
|
8.8 ± 3.8
|
|
FFMI (%)
|
10.8 ± 1.4
|
|
Cardiac findings
|
|
QT interval (mm)
|
406 ± 54
|
|
QTc interval (mm)
|
385 ± 31
|
|
QT/QTc
|
1 ± 0.1
|
|
Pericardial effusion
|
34 (27%)
|
|
LVEF (%)
|
63 ± 10
|
|
LV mass (g)
|
80 ± 22
|
|
Biological findings
|
|
Albumin (38–52 g/l)
|
36.9 ± 7.1
|
|
Transthyretin (0.21–0.45 g/l)
|
0.248 ± 0.102
|
|
CRP (< 5 mg/l)
|
6.5 ± 23.7
|
|
BNP (< 100 pg /l)
|
54 ± 70
|
|
Potassium (3.7–4.7 mmol/l)
|
3.8 ± 0.6
|
|
Calcium (2.12–2.52 mmol/l)
|
2.2 ± 0.1
|
|
Phosphorus (0.8–1.45 mmol/l)
|
1.1 ± 0.3
|
|
Magnesium (0.70–1.00 mmol/l)
|
0.8 ± 0,1
|
|
Patients with Hypertransaminasemiaa
|
34 (27%)
|
|
AST (15–37 UI/l)
|
137.6 ± 425.8
|
|
ALT (12–78 UI/l)
|
170.1 ± 371.4
|
|
Total Cholesterol (C) (3.00–6.00 mmol/l)
|
4.2 ± 1.4
|
|
HDL-C (0.8–1.9 mmol/l)
|
1.8 ± 0.7
|
|
LDL-C (< 4.1 mmol/l)
|
2.1 ± 1.1
|
|
Total TG (< 1.7 mmol/l)
|
0.9 ± 0.7
|
